Evolving role of Ac-225-PSMA Radioligand Therapy in mCRPC
225Ac-PSMA RLT is an efficacious and safe treatment option for [...]
Real-world data analysis of efficacy and survival after Lu-177 PSMA
177Lu-PSMA radioligand therapy provides a significant response rate with a [...]
PSMA Lu-177 x Ac-225
Available since 2015, the treatment of patients with metastatic castration-resistant [...]
First clinical results for PSMA TAT using Ac-225-PSMA-I&T in advanced mCRPC patients
First clinical results for PSMA targeted alpha therapy using 225Ac-PSMA-I&T [...]
TheraP Trial Design in Prostate Cancer
Interesting interview with Pr. Michael Hofman about TheraP Trial Design [...]